TY - JOUR
T1 - Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
AU - Tan, Bryan
AU - Pan, Xin Hui
AU - Chew, Han Shi Jocelyn
AU - Goh, Rachel Sze Jen
AU - Lin, Chaoxing
AU - Anand, Vickram Vijay
AU - Lee, Ethan Cheng Zhe
AU - Chan, Kai En
AU - Kong, Gwyneth
AU - Ong, Christen En Ya
AU - Chung, Hui Charlotte
AU - Young, Dan Yock
AU - Chan, Mark Y.
AU - Khoo, Chin Meng
AU - Mehta, Anurag
AU - Muthiah, Mark Dhinesh
AU - Noureddin, Mazen
AU - Ng, Cheng Han
AU - Chew, Nicholas W.S.
AU - Chin, Yip Han
N1 - Funding Information:
MYC: Speaker’s fees and research grants Astra Zeneca, Abbott Technologies and Boston Scientific. MN: MN has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Terns, Siemens and Roche diagnostic; he has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking and Zydus; he is a minor shareholder or has stocks in Anaetos, Rivus Pharma and Viking. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2023/8
Y1 - 2023/8
N2 - Background: Recent studies suggest that tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects. This systematic review and meta-analysis aims to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity. Methods: Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide’s weight loss efficacy for these patients. A single arm meta-analysis of proportions estimated primary outcomes, ≥5%, ≥10%, and ≥15% weight loss, and adverse events (AEs); while meta-analysis of means estimated secondary outcomes. Comparative meta-analysis was conducted between tirzepatide and control arms where mean differences and odds ratios were estimated for continuous and dichotomous outcomes respectively. Results: RCTs included in this study revealed that among 5800 patients, 78.22% (95% CI: 72.15% to 83.73%), 55.60% (95% CI: 46.54% to 64.47%), 32.28% (95% CI: 23.17% to 42.12%) achieved ≥5%, ≥10%, and ≥15% weight loss, respectively. Tirzepatide 5 mg demonstrated weight loss superiority relative to placebo (MD: −12.47 kg, 95% CI: −13.94 kg to −11.00 kg) and semaglutide (n = 1409, MD: −1.90 kg, 95% CI: −2.97 kg to −0.83 kg) with dose-dependent increase for 10 mg and 15 mg doses. The comparison between tirzepatide and semaglutide was examined in the SURPASS-2 trial that was included in this systematic review. For AEs, there was increase odds of experiencing gastrointestinal AEs with tirzepatide compared to placebo, but no significant difference with semaglutide. Conclusion: Tirzepatide has significant potential as a weight loss drug in patients with overweight and obesity, with little increase in AEs compared to other weight loss drugs. With its ability to concurrently target multiple aspects of metabolic syndrome, it should be considered as the next helm of weight loss therapies.
AB - Background: Recent studies suggest that tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects. This systematic review and meta-analysis aims to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity. Methods: Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide’s weight loss efficacy for these patients. A single arm meta-analysis of proportions estimated primary outcomes, ≥5%, ≥10%, and ≥15% weight loss, and adverse events (AEs); while meta-analysis of means estimated secondary outcomes. Comparative meta-analysis was conducted between tirzepatide and control arms where mean differences and odds ratios were estimated for continuous and dichotomous outcomes respectively. Results: RCTs included in this study revealed that among 5800 patients, 78.22% (95% CI: 72.15% to 83.73%), 55.60% (95% CI: 46.54% to 64.47%), 32.28% (95% CI: 23.17% to 42.12%) achieved ≥5%, ≥10%, and ≥15% weight loss, respectively. Tirzepatide 5 mg demonstrated weight loss superiority relative to placebo (MD: −12.47 kg, 95% CI: −13.94 kg to −11.00 kg) and semaglutide (n = 1409, MD: −1.90 kg, 95% CI: −2.97 kg to −0.83 kg) with dose-dependent increase for 10 mg and 15 mg doses. The comparison between tirzepatide and semaglutide was examined in the SURPASS-2 trial that was included in this systematic review. For AEs, there was increase odds of experiencing gastrointestinal AEs with tirzepatide compared to placebo, but no significant difference with semaglutide. Conclusion: Tirzepatide has significant potential as a weight loss drug in patients with overweight and obesity, with little increase in AEs compared to other weight loss drugs. With its ability to concurrently target multiple aspects of metabolic syndrome, it should be considered as the next helm of weight loss therapies.
KW - Humans
KW - Overweight/drug therapy
KW - Obesity/drug therapy
KW - Gastric Inhibitory Polypeptide
KW - Anti-Obesity Agents/adverse effects
KW - Weight Loss
KW - Diabetes Mellitus, Type 2
KW - Hypoglycemic Agents
KW - Glucagon-Like Peptide-1 Receptor
UR - http://www.scopus.com/inward/record.url?scp=85160663656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160663656&partnerID=8YFLogxK
U2 - 10.1038/s41366-023-01321-5
DO - 10.1038/s41366-023-01321-5
M3 - Review article
C2 - 37253796
AN - SCOPUS:85160663656
SN - 0307-0565
VL - 47
SP - 677
EP - 685
JO - International Journal of Obesity
JF - International Journal of Obesity
IS - 8
ER -